NCT04565379

Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients

A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Shaperon · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia patients

Conditions

• COVID19 Pneumonia

Interventions

Type	Name	Description
DRUG	NuSepin® 0.1 mg	NuSepin® 0.1 mg
DRUG	NuSepin® 0.2 mg	NuSepin® 0.2 mg
DRUG	Placebo	Normal Saline

Timeline

• Start date: 2020-09-24
• Primary completion: 2021-04-13
• Completion: 2021-04-13
• First posted: 2020-09-25
• Last updated: 2022-01-28

Locations

5 sites across 1 country: Romania